Fiscal year 2025 ovarian cancer research program
Ended Awarded Last action
- Contract number
- HT942525F0068
- Awardee
-
Leidos, Inc. UEI QLNMVC12KWY3 Part of Leidos Holdings, Inc.
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $254,999
Award facts
- Opportunity
-
- Meeting, Programmatic, and Administrative Support Services Pre-Solicitation · W81XWH22R0025 · Posted Aug 16, 2021
- Contract value 100% obligated
- $254,999.42 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Reston, VA 20190, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $7,255 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $247,744 |
About this award
Leidos, Inc. has been awarded a delivery order valued at approximately $255K under the Fiscal Year 2025 Ovarian Cancer Research Program, funded by the Defense Health Agency. This cost-plus-fixed-fee contract, with an ultimate completion date of March 14, 2026, represents work to be performed in Herndon, VA. The award carries no set-aside designation, indicating competitive procurement. This delivery order supports the Defense Health Agency's medical research initiatives, which focus on advancing treatment and prevention strategies for ovarian cancer—a critical priority within the Department of Defense's broader health research portfolio.
The contract was awarded to Leidos' Services Operating Segment (operating as SAIC), a subsidiary of Leidos Holdings, Inc., a major global technology and engineering solutions provider with extensive experience supporting federal agencies across defense, intelligence, and health sectors. Leidos has demonstrated substantial capabilities in medical research program support through numerous contracts with agencies including the National Cancer Institute and Defense Health Agency, covering research areas such as cancer, infectious diseases, and rare disease investigations. The company's experience with research-focused initiatives and established relationships with federal health agencies position it well to execute this ovarian cancer research support mission.
Quick answers
Who was awarded contract HT942525F0068?
HT942525F0068 was awarded to Leidos, Inc. by Defense Health Agency (Department of Defense) on March 15, 2025.
How much is contract HT942525F0068 worth?
The government has obligated $254,999 on HT942525F0068.
Is contract HT942525F0068 an order under another contract?
Yes. HT942525F0068 is a delivery order under HT942523D0002, an indefinite delivery contract.
Was contract HT942525F0068 competed?
The extent of competition for HT942525F0068 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award